A four-year-old boy from Oklahoma, born with congenital CMV, experiences the world of sound for the first time after ...

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program ...

One-third of congenital cytomegalovirus-related hearing loss would be missed without universal screening programs.

Due to improvements in recognition and management of their multisystem disease, the long‐term survival of infants, children, and adolescents with trisomy 21 and congenital heart disease now matches ...

BofA lowered the firm’s price target on Moderna (MRNA) to $21 from $24 and keeps an Underperform rating on the shares. The firm’s 2025 revenue estimates increase by 3% due to higher-than-expected ...

Moderna Inc. (MRNA) reported its third-quarter 2025 earnings on November 6, revealing a significant earnings beat with an EPS of -0.51, surpassing the forecasted -2.05. This unexpected result was ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion ...

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) through universal screening demonstrates the critical importance of early ...